Symbol="YMAB"
AssetType="Common Stock"
Name="Y mAbs Therapeutics"
Description="Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of new antibody-based therapeutics for the treatment of cancer in the United States. The company is headquartered in New York, New York."
CIK="1722964"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="750 THIRD AVENUE, 9TH FLOOR, NEW YORK, NY, US"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="317897000"
EBITDA="-57817000"
PERatio="None"
PEGRatio="None"
BookValue="2.469"
DividendPerShare="0"
DividendYield="0"
EPS="-1.79"
RevenuePerShareTTM="1.717"
ProfitMargin="-0.985"
OperatingMarginTTM="-0.782"
ReturnOnAssetsTTM="-0.223"
ReturnOnEquityTTM="-0.557"
RevenueTTM="75032000"
GrossProfitTTM="57700000"
DilutedEPSTTM="-1.79"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="0.931"
AnalystTargetPrice="12.71"
TrailingPE="-"
ForwardPE="119.05"
PriceToSalesRatioTTM="5.21"
PriceToBookRatio="2.056"
EVToRevenue="2.523"
EVToEBITDA="-0.852"
Beta="0.693"
num_52WeekHigh="20.48"
num_52WeekLow="2.7"
num_50DayMovingAverage="7.99"
num_200DayMovingAverage="6.47"
SharesOutstanding="43677800"
DividendDate="None"
ExDividendDate="None"
symbol="YMAB"
open="7.10"
high="7.10"
low="6.86"
price="7.09"
volume="89871.00"
latest_trading_day="2023-07-14"
previous_close="7.07"
change="0.02"
change_percent="0.2829%"
aroon_positive_momentum_days="73"
aroon_negative_momentum_days="0"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Buy Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="73"
Volume_recent_avg="568308"
Change_recent_avg="-0.01"
Delta_recent_avg="0.51"
Variance_recent_avg="0.26"
Change_ratio_recent_avg="-0.18"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="positive"
Aroon_change="FALSE"
Aroon_momentum_positive="73"
Aroon_momentum_negative="27"
image_negative_thumbnail_id_1="171"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0005.jpeg"
image_negative_thumbnail_id_2="1101"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0134.jpeg"
image_neutral_thumbnail_id_1="580"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0019.jpeg"
image_neutral_thumbnail_id_2="579"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0020.jpeg"
image_positive_thumbnail_id_1="963"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0125.jpeg"
image_positive_thumbnail_id_2="632"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0076.jpeg"
image_professor_thumbnail_id_1="1175"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0009.jpeg"
image_professor_thumbnail_id_2="1170"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0004.jpeg"
